[Treating chronic occlusive arterial disease].
The basis for the treatment of chronic occlusive arterial disease, in whatever stage, is the management of the cardiovascular risk factors as a secondary preventive measure. In the absence of contraindications, every symptomatic POAD patient should be given an antiplatelet agent. In stage I disease, prevention of progression is the overriding aim. In stage II, risk factor management and an antiplatelet agent are indicated. In addition to a walking exercise program, the reconstruction of occluded vessels may be indicated. The decision to apply interventional treatment or vascular surgery in stage II and IV disease; must be based on the morphology of the vascular lesion and concomitant diseases. If revascularization is not possible, treatment with PGE1 is recommended. As a life-saving measure when all else has failed, an amputation must be done.
Rottman
M
M
Medizinische Klinik Nord-Angiologie/Diabetologie, Klinikum Dortmund gGmbH. marcusrottmann@t-online.de
Koepchen
J
J
Angelkort
B
B
D000527:Alprostadil / Q000627:therapeutic use; D000671:Amputation, Surgical; D000800:Angioplasty, Balloon; D001157:Arterial Occlusive Diseases / Q000145:classification / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002908:Chronic Disease; D048909:Diabetes Complications; D006801:Humans; D006973:Hypertension / Q000150:complications; D007866:Leg / Q000098:blood supply*; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D014665:Vasodilator Agents / Q000627:therapeutic use; D016138:Walking
D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D000527:Alprostadil